CAS 943540-74-7

Formel: C20H12F2N6

InChl: InChI=1S/C20H12F2N6/c21-20(22,15-3-4-16-14(12-15)2-1-9-24-16)19-26-25-18-6-5-17(27-28(18)19)13-7-10-23-11-8-13/h1-12H

InChI Key: KOAWAWHSMVKCON-UHFFFAOYSA-N

SMILES: C1=CC2=C(C=CC(=C2)C(C3=NN=C4N3N=C(C=C4)C5=CC=NC=C5)(F)F)N=C1

JNJ-38877618

CAS: 943540-74-7

JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively).

Formel: C₂₀H₁₂F₂N₆

Reinheit: 98.84% - 99.74%

Farbe und Form: Yellow Solid

Molekulargewicht: 374.3463

Ref: TM-T15617

JNJ-38877618

CAS: 943540-74-7

JNJ-38877618

Formel: C₂₀H₁₂F₂N₆

Reinheit: ≥98%

Molekulargewicht: 374.35

Ref: 54-BUP08597

JNJ-38877618

CAS: 943540-74-7

6-(Difluoro(6-(pyridin-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl)quinoline

Formel: C₂₀H₁₂F₂N₆

Reinheit: 99%

Molekulargewicht: 374.35

Ref: IN-DG00794771

JNJ-38877618(OMO-1)

CAS: 943540-74-7

JNJ-38877618(OMO-1) is a novel synthetase inhibitor that has been shown to have potent anti-tumor activity in vitro and in vivo. This drug selectively inhibits the synthesis of siderophores by the iron transporter, ferric reductase, and is also effective against neutrophil chemotaxis. JNJ-38877618(OMO-1) has a low bioavailability and poor solubility, which limits its use as an oral drug. However, it has been shown to be safe when used at high doses in mice. The safety profile of this drug is yet to be determined during clinical development.

Formel: C₂₀H₁₂F₂N₆

Reinheit: Min. 95%

Molekulargewicht: 374.35 g/mol

Ref: 3D-TMB54074